Exscientia plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EXAI research report →
About the company
Exscientia plc is a pioneering pharmatech firm that leverages artificial intelligence (AI) to revolutionize drug discovery and development. The company provides a comprehensive, AI-driven platform that spans the entire drug development lifecycle. This integrated system supports crucial stages, including identifying disease targets, designing potential drug candidates, developing translational models, and optimizing patient selection for clinical trials.
- CEO
- David Hallett
- IPO
- 2021
- Employees
- 483
- HQ
- Oxford, GB
Price Chart
- Market Cap
- $633.18M
- P/E
- -3.07
- P/S
- 23.62
- P/B
- 1.25
- EV/EBITDA
- -1.62
- Div Yield
- 0.00%
- Gross Margin
- -36.48%
- Op Margin
- -876.56%
- Net Margin
- -726.94%
- ROE
- -38.96%
- ROIC
- -35.37%
- Revenue
- $20.08M · -26.24%
- Net Income
- $-145,963,000 · -22.94%
- EPS
- $-1.18 · -21.65%
- Op Income
- $-176,004,000
- FCF YoY
- -76.27%
- 52W High
- $4.84
- 52W Low
- $4.84
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.83
- Avg Volume
- 0
Get TickerSpark's AI analysis on EXAI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our EXAI coverage
Recent articles, reports, and earnings notes.
No research on EXAI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EXAI report →Similar companies
Peers in the same neighborhood.